Why Array Technologies, Inc. (ARRY) Could Be a Smart Value Investment for Your Portfolio

Investing in the stock market with confidence and taking advantage of opportunities is a common goal for both new and experienced investors. To help guide their buy and sell decisions, many investors rely on a methodology that takes into account various factors, such as the Zacks Style Scores. These scores are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum. One particular type of investment that value investors often focus on is finding good stocks at good prices, and discovering which companies are trading under their true value. The Value Style Score takes into account ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to highlight the most attractive and discounted stocks. One such company that has a strong Value Style Score of A and VGM Score of B is Array Technologies, Inc. (ARRY), a biopharmaceutical company based in Boulder, CO. The company is focused on the discovery, development, and commercialization of targeted small molecule drugs for treating cancer and other high-burden diseases. It has one marketed combination therapy in its portfolio – Braftovi (encorafenib) plus Mektovi (binimetinib) – which is approved for treating unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. The company is also conducting label expansion studies for the combination therapy. ARRY boasts a forward earnings multiple of 14X, a PEG Ratio of 0.6, a Price/Cash Flow ratio of 2.8X, and a Price/Sales ratio of 1.1X. In addition to its strong valuation metrics, ARRY has an average earnings surprise of 40% and has seen four analysts revise their earnings estimate upwards in the last 60 days for fiscal 2025. The Zacks Consensus Estimate has increased to $0.63 from $0.63. Investors should consider ARRY for their portfolios due to its solid Zacks Ranks, notable earnings and valuation metrics, and impressive Value and VGM Style Scores. To stay up-to-date on the latest recommendations from Zacks Investment Research, investors can download the 7 Best Stocks for the Next 30 Days report today.